John P. Leonard¹, Marek Trneny², Nathan H. Fowler³, Xiaonan Hong⁴, Jun Zhu⁵, Huilai Zhang⁶, Fritz Offner⁷, Adriana Scheliga⁸, Grzegorz Nowakowski⁹, Antonio Pinto¹⁰, Francesca Re¹¹, Laura Maria Fogliatto¹², Phillip Scheinberg¹³, Ian Flinn¹⁴, Claudia Moreira¹⁵, Myron Czuczman¹⁶, Stacey Kalambakas¹⁶, Pierre Fustier¹⁷, Chengqing Wu¹⁶, John Gribben¹⁸, Koji Izutsu¹⁹ (1.Meyer Cancer Center, Weill Cornell Medicine and New York Presbyterian Hospital, New York, NY, United States of America, 2.Charles University Hospital, Prague, Czech Republic, 3.The University of Texas MD Anderson Cancer Center, Houston, TX, United States of America, 4.Fudan University Shanghai Cancer Center, Shanghai, People's Republic of China, 5.Beijing Cancer Hospital, Beijing, People's Republic of China, 6.Tianjin Medical University Cancer Institute and Hospital, Tianjin, People's Republic of China, 7.UZ Gent, Gent, Kingdom of Belgium, 8.INCA Instituto Nacional de Cancer, Rio de Janeiro, Federative Republic of Brazil, 9.Mayo Clinic, Rochester, MN, United States of America, 10.Istituto Nazionale Per Lo Studio E La Cura dei Tumori Fondazione Giovanni Pascale, Napoli, Italian Republic, 11.Azienda Ospedaliero-Universitaria di Parma, Parma, Italian Republic, 12.Hospital de Clinicas de Porto Alegre, Porto Alegre, Federative Republic of Brazil, 13.Division of Hematology, Hospital A Beneficencia Portuguesa, Sao Paulo, Federative Republic of Brazil, 14.SCRI Tennessee Oncology Nashville, Nashville, TN, United States of America, 15.Instituto Portugues de Oncologia do Porto Francisco Gentil Epe, Porto, Portuguese Republic, 16.Celgene Corporation, Summit, NJ, United States of America, 17.Celgene Corporation, Boudry, Swiss Confederation, 18.Centre for Haemato-Oncology, Barts Cancer Institute, London, United Kingdom of Great Britain and Northern Ireland, 19.National Cancer Center Hospital, Tokyo, Japan)

Yasuhito Terui¹, John P. Leonard², Nathan H. Fowler³, Franck Morschhauser⁴, Koji Izutsu⁵, Yosuke Minami⁶, Noriko Fukuhara⁷, Tatsuro Jo⁸, Go Yamamoto⁹, Takayuki Ishikawa¹⁰, Tsutomu Kobayashi¹¹, Toru Kiguchi¹², Hirokazu Nagai¹³, Kiyoshi Ando¹⁴, Hisayuki Yokoyama¹⁵, Michiaki Koike¹⁶, Koji Kato¹⁷, Tomoko Ohtsu¹⁸, Stacey Kalambakas¹⁹, Pierre Fustier²⁰, Shuichi Midorikawa¹⁸, Kensei Tobinai⁵ (1.Department of Hematology Oncology, The Cancer Institute Hospital of JFCR, Tokyo, Koto-ku, Japan, 2.Meyer Cancer Center, Weill Cornell Medicine and New York Presbyterian Hospital, New York, NY, United States of America, 3.Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, United States of America, 4.University of Lille, CHU Lille, EA 7365 - GRITA - Groupe de Recherche sur les formes Injectables et les Technologies Associee, Lille, France Metropolitan, 5.Department of Hematology, National Cancer Center Hospital, Tokyo, Japan, 6.Department of Hematology, National Cancer Center Hospital East, Chiba, Japan, 7.Department of Hematology and Rheumatology, Tohoku University Hospital, Sendai, Japan, 8.Department of Hematology, Japanese Red Cross Nagasaki Genbaku Hospital, Nagasaki, Japan, 9.Department of Hematology, Toranomon Hospital, Tokyo, United States of America, 10.Department of Hematology, Kobe City Medical Center General Hospital, Kobe, Japan, 11.Division of Hematology and Oncology, Kyoto Prefectural University of Medicine, Kyoto, Japan, 12.Department of Hematology, Chugoku Central Hospital, Fukuyama, Japan, 13.Department of Hematology and Oncology Research, Nagoya Medical Center, Clinical Research Center, Nagoya, Japan, 14.Department of Hematology and Oncology, Tokai University School of Medicine, Tokyo, Japan, 15.Department of Hematology, National Hospital Organization Sendai Medical Center, Sendai, Japan, 16.Department of Hematology, Juntendo University Shizuoka Hospital, Tokyo, Japan, 17.Department of Medicine and Biosystemic Science, Kyushu University Faculty of Medicine, Fukuoka City, Japan, 18.Celgene K.K., Tokyo, Japan, 19.Celgene Corporation, Summit, NJ, United States of America, 20.Celgene Corporation, Boudry, Swiss Confederation)

Dai Maruyama¹, Noriko Fukuhara², Koji Izutsu^1,3, Toshiki Uchida⁴, Shigeru Kusumoto⁵, Junya Kuroda⁶, Chisako Iriyama⁷, Masamitsu Yanada⁷, Norifumi Tsukamoto⁸, Yoko Suehiro⁹, Hironobu Minami¹⁰, Hirokazu Nagai¹¹, Shigeo Masuda¹², Kensei Tobinai¹ (1.Hematology, National Cancer Center Hospital, Tokyo, Japan, 2.Hematology and Rheumatology, Tohoku University Hospital, Sendai, Japan, 3.Hematology, Toranomon Hospital, Tokyo, Japan, 4.Hematology Oncology, Japanese Red Cross Nagoya Daini Hospital, Nagoya, Japan, 5.Hematology Oncology, Nagoya City University Hospital, Nagoya, Japan, 6.Hematology Oncology, Kyoto Prefectural University of Medicine, Kyoto, Japan, 7.Hematology and Cell Therapy, Aichi Cancer Center, Nagoya, Japan, 8.Medicine and Clinical Science, Gunma University Hospital, Gunma, Japan, 9.Hematology, National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan, 10.Medical Oncology Hematology, Kobe University Hospital, Kobe, Japan, 11.Hematology, National Hospital Organization Nagoya Medical Center, Nagoya, Japan, 12.Bayer Yakuhin, Ltd., Osaka, Japan)

Koji Kato¹, Koji Izutsu^2,3, Hitoshi Kiyoi⁴ (1.Hematology, Oncology and Cardiovascular Medicine, Kyushu University Hospital, Japan, 2.Department of Hematology, National Cancer Center Hospital, Tokyo, Japan, 3.Department of Hematology, Toranomon Hospital, Tokyo, Japan, 4.Department of Hematology and Oncology, Nagoya University, Nagoya, Japan)

Michinori Ogura¹, Juan Manuel Sancho², Seok-Goo Cho³, Hideyuki Nakazawa⁴, Junji Suzumiya⁵, Gayane Tumyan⁶, Jin Seok Kim⁷, Anne Lennard⁸, Jose M. Mariz⁹, Nikolai Ilyin¹⁰, Wojciech Jurczak¹¹, Aurelio Lopez Martinez¹², Olga Samoilova¹³, Edvard Zhavrid¹⁴, Eduardo Yanez Ruiz¹⁵, Marek Trneny¹⁶, Leslie Popplewell¹⁷, Christian Buske¹⁸, Won Seog Kim¹⁹, SangJoon Lee²⁰, YunJu Bae²⁰, JeongAh Park²⁰, YeonMi Lee²⁰, SangEun Han²⁰, Larry W. Kwak²¹ (1.Department of Hematology and Oncology, Kasugai Municipal Hospital, Kasugai, Aichi, Japan, 2.Hematology Department, ICO-IJC-Hospital Germans Trias i Pujol, Badalona, Barcelona, Spain, 3.Department of Hematology, Leukemia Research Institute, Seoul St. Mary's Hematology Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea, 4.Department of Hematology, Shinshu University School of Medicine, Matsumoto, Nagano, Japan, 5.Innovative Cancer Center/Oncology-Hematology, Shimane University Hospital, Izumo, Shimane, Japan, 6.Department of Chemotherapy of Hemoblastosis, Blokhin Russian Cancer Research Center, Moscow, Moscow, Russian Federation, 7.Department of Internal Medicine, Yonsei University College of Medicine, Severance Hospital, Seoul, Republic of Korea, 8.Northern Institute for Cancer Care, Newcastle University, Newcastle upon Tyne, Tyne-Wear, United Kingdom of Great Britain and Northern Ireland, 9.Department of Hematology, Instituto Potugues de Oncologia, Porto, Portuguese Republic, 10.Russian Research Center for Radiology and Surgical Technologies, Ministry of Health of the Russian Federation, St. Petersburg, Russian Federation, 11.Department of Haematology, Jagiellonian University, Krakow, Malopolskie, Republic of Poland, 12.Hospital Arnau de Vilanova, Valencia, Comunidad Valenciana, Spain, 13.Nizhny Novogorod Regional Clinical Hospital, Nizhniy Novgorod, Nizhniy Novgorod region, Russian Federation, 14.N N Alexandrov Republican Scientific and Practical Centre of Oncology and Medical Radiology, Minsk, Republic of Belarus, 15.Universidad de la Frontera, Temuco, Cautin, Republic of Chile, 16.First Department of Medicine - Department of Hematology, General University Hospital and Charles University in Prague, Prague, Czech Republic, 17.City of Hope, Duarte, Califonia, United States of America, 18.Comprehensive Cancer Center Ulm, Comprehensive Cancer Center Ulm, Ulm, Baden Wurttemberg, Federal Republic of Germany, 19.Division of Hematology and Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea, 20.Clinical Development Division, Celltrion, Inc., Incheon, Republic of Korea, 21.Toni Stephenson Lymphoma Center and Department of Hematology and Hematopoietic Cell Transplantation City of Hope, Duarte, Califonia, United States of America)

Naohiro Sekiguchi¹, Toshiki Uchida², Shinsuke Wada³, Shintaro Hiro³, Kei Fukuhara³, Kentaro Tajima⁴, Kenichi Ishizawa⁵ (1.National Hospital Organization Disaster Medical Center, Tokyo, Japan, 2.Japanese Red Cross Nagoya Daini Hospital, Aichi, Japan, 3.Pfizer R&D Japan, Tokyo, Japan, 4.Pfizer Japan Inc., Tokyo, Japan, 5.Yamagata University Faculty of Medicine, Yamagata, Japan)